India, May 31 -- Genentech, a member of the Roche Group (RHHBY), announced positive final results from the overall survival analysis of the Phase III INAVO120 study. These data showed Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement in overall survival for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
The Itovebi-based regimen demonstrated a meaningful overall survival benefit compared with palbocicli...